NIH Study Probes How Pepto-Bismol Reshapes Your Gut Microbiome
A completed NIAID Phase 1 trial investigates whether a common OTC stomach remedy disrupts healthy gut bacteria — and how the body responds.
Summary
Bismuth subsalicylate (BSS), the active ingredient in Pepto-Bismol, is used by millions for diarrhea and upset stomach, yet its effects on the gut microbiome remain poorly characterized. This NIH-sponsored Phase 1 trial enrolled healthy adults aged 18–50 to take a standard therapeutic dose of BSS four times daily for two days — mirroring real-world use. Researchers tracked gut bacteria changes across six study visits spanning up to 18 weeks, collecting stool samples at each point along with optional blood, saliva, urine, and intestinal tissue via colonoscopy. The goal was to establish a baseline understanding of how even short-term use of this widely available OTC compound alters the microbial community and the host immune and metabolic response — knowledge that has broad implications for gut health and medication safety.
Detailed Summary
Bismuth subsalicylate (BSS) is one of the most commonly used over-the-counter remedies in the world, sold under brand names like Pepto-Bismol and Pink Bismuth. Despite its widespread use for diarrhea, nausea, and indigestion, surprisingly little is known about how even brief exposure to BSS affects the trillions of bacteria living in the human gut. This knowledge gap matters because gut microbiome disruptions — even transient ones — have been linked to downstream effects on immune function, metabolism, and long-term health.
The National Institute of Allergy and Infectious Diseases (NIAID) sponsored this Phase 1 clinical trial to directly address that gap. Healthy adults aged 18 to 50 were recruited and administered BSS at standard therapeutic doses — four times per day for two days — the same regimen a person would follow to treat acute diarrhea. The study design included six clinic visits over up to 18 weeks, allowing researchers to capture microbiome dynamics before, during, and well after BSS exposure.
Stool samples were the primary data collection tool, with optional biospecimens including blood, saliva, and urine also gathered. A subset of participants underwent optional colonoscopies to obtain intestinal mucosal tissue, enabling analysis of local host immune and cellular responses beyond what stool alone can reveal. Dietary surveys and health questionnaires added contextual data to help interpret individual variability.
The extended 18-week follow-up window is a notable strength, designed to determine whether any microbiome changes induced by BSS are transient or persist long after the two-day exposure ends. This has direct relevance for understanding recovery dynamics and whether certain bacterial species are disproportionately affected.
For clinicians and health-conscious individuals alike, these findings will help contextualize the true risk-benefit profile of one of the world's most trusted stomach remedies. Caveats include the study's focus on healthy young adults and the short intervention window, which may not reflect repeated or chronic use patterns common in older populations.
Key Findings
- BSS (Pepto-Bismol) was administered at standard therapeutic doses for 2 days to assess real-world microbiome impact.
- Stool samples collected across 18 weeks enable tracking of both acute disruption and long-term microbiome recovery.
- Optional colonoscopies allow direct sampling of intestinal tissue to capture host immune responses beyond stool analysis.
- Study is NIAID-sponsored and completed, with results anticipated to clarify OTC medication safety for gut health.
- Findings could reframe how clinicians counsel patients on routine use of bismuth-containing antidiarrheal agents.
Methodology
Phase 1 single-arm interventional trial enrolling healthy adults aged 18–50, with BSS administered at standard therapeutic dosing (4x/day for 2 days). Six study visits over up to 18 weeks captured longitudinal stool microbiome data, supplemented by optional blood, saliva, urine, and colonoscopy-derived tissue samples.
Study Limitations
This summary is based on the abstract and trial registration only, as the full study results are not yet publicly available. The study enrolled only healthy young adults aged 18–50, limiting generalizability to older populations or those with chronic gastrointestinal conditions. The two-day intervention reflects acute use only and does not address repeated or long-term BSS exposure.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: